Literature DB >> 3117338

Adrenal responses to subtotal parathyroidectomy for primary hyperparathyroidism.

R Pacifici1, H M Perry, W Shieber, E Biglieri, D M Droke, L V Avioli.   

Abstract

Although it is well known that hypertension is often associated with primary hyperparathyroidism and that parathyroidectomy reverses or reduces this abnormality, the etiology of elevated blood pressure in hyperparathyroidism is still conjectural. We have analyzed serum calcium, blood pressure, and metabolites of adrenal cortical hormones before and after surgical therapy for hyperparathyroidism in 10 normotensive and six hypertensive patients with primary hyperparathyroidism. Successful parathyroidectomy lowered serum calcium (P less than 0.01) and diastolic blood pressure (P less than 0.05) in all subjects. Mean urinary aldosterone and Porter-Silber chromagens were within normal limits preoperatively in normotensive as well as hypertensive subjects. After parathyroidectomy, aldosterone levels as well as Porter-Silber chromagens decreased significantly in all patients (P less than 0.01). However, when normotensive and hypertensive subjects were analyzed separately, the decrease in aldosterone levels was significant only in the normotensive group (P less than 0.05) whereas the decrease in Porter-Silber chromagens reached significancy only in the hypertensive group (P less than 0.01). The results indicate that surgical therapy for hyperparathyroidism lowers serum calcium and blood pressure and is associated with a decrease in the excretion of adrenal steroid metabolites. It is suggested that the temporal relationship which exists between ionized calcium and steroidogenesis in hyperparathyroid patients contributes at least in part to the generalized decrease in blood pressure observed after successful parathyroidectomy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117338     DOI: 10.1007/bf02563790

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  35 in total

1.  Hypertension in hyperparathyroidism.

Authors:  J HELLSTROM; G BIRKE; C A EDVALL
Journal:  Br J Urol       Date:  1958-03

2.  The determination of 17,21-dihydroxy-20-ketosteroids in urine and plasma.

Authors:  R H SILBER; C C PORTER
Journal:  J Biol Chem       Date:  1954-10       Impact factor: 5.157

3.  Role of calcium and cAMP in the action of adrenocorticotropin on aldosterone secretion.

Authors:  I Kojima; K Kojima; H Rasmussen
Journal:  J Biol Chem       Date:  1985-04-10       Impact factor: 5.157

Review 4.  Water hardness and cardiovascular diseases.

Authors:  G W Comstock
Journal:  Am J Epidemiol       Date:  1979-10       Impact factor: 4.897

5.  Primary hyperparathyroidism: clinical and biochemical features.

Authors:  L E Mallette; J P Bilezikian; D A Heath; G D Aurbach
Journal:  Medicine (Baltimore)       Date:  1974-03       Impact factor: 1.889

6.  Mortality and hardness of local water-supplies.

Authors:  M D Crawford; M J Gardner; J N Morris
Journal:  Lancet       Date:  1968-04-20       Impact factor: 79.321

7.  Interrelationship of parathyroid and adrenocortical function in calcium homeostasis in the rat.

Authors:  G A Williams; W C Peterson; E N Bowser; W J Henderson; G K Hargis; N J Martinez
Journal:  Endocrinology       Date:  1974-09       Impact factor: 4.736

8.  Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy.

Authors:  P Erne; P Bolli; E Bürgisser; F R Bühler
Journal:  N Engl J Med       Date:  1984-04-26       Impact factor: 91.245

9.  Reduction of blood pressure with calcium supplementation in young adults.

Authors:  J M Belizan; J Villar; O Pineda; A E Gonzalez; E Sainz; G Garrera; R Sibrian
Journal:  JAMA       Date:  1983-03-04       Impact factor: 56.272

10.  Glucagon secretion in patients with hypoparathyroidism: effect of serum calcium on glucagon release.

Authors:  R Torella; D Giugliano; G Scognamiglio; N Passariello; A Tirelli
Journal:  J Clin Endocrinol Metab       Date:  1982-02       Impact factor: 5.958

View more
  5 in total

1.  The effect of vitamin D3 supplementation on markers of cardiovascular health in hyperparathyroid, vitamin D insufficient women: a randomized placebo-controlled trial.

Authors:  Lise Sofie Bislev; Lene Langagergaard Rødbro; Jesper Nørgaard Bech; Erling Bjerregaard Pedersen; Alisa D Kjaergaard; Søren Andreas Ladefoged; Lars Rolighed; Tanja Sikjaer; Lars Rejnmark
Journal:  Endocrine       Date:  2018-07-24       Impact factor: 3.633

Review 2.  Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea-what do we know so far?

Authors:  Huai Heng Loh; Norlela Sukor
Journal:  J Hum Hypertens       Date:  2019-12-10       Impact factor: 3.012

3.  Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial.

Authors:  Andreas Tomaschitz; Astrid Fahrleitner-Pammer; Burkert Pieske; Nicolas Verheyen; Karin Amrein; Eberhard Ritz; Katharina Kienreich; Jörg H Horina; Albrecht Schmidt; Elisabeth Kraigher-Krainer; Caterina Colantonio; Andreas Meinitzer; Stefan Pilz
Journal:  BMC Endocr Disord       Date:  2012-09-13       Impact factor: 2.763

4.  Angiotensin-Converting Enzyme Inhibition and Parathyroid Hormone Secretion.

Authors:  Sarah Zaheer; Jenifer M Brown; Molly Connors; Jonathan S Williams; Gail K Adler; Anand Vaidya
Journal:  Int J Endocrinol       Date:  2017-07-20       Impact factor: 3.257

Review 5.  The Interplay Between the Renin-Angiotensin-Aldosterone System and Parathyroid Hormone.

Authors:  Ming-Hui Zheng; Fu-Xing-Zi Li; Feng Xu; Xiao Lin; Yi Wang; Qiu-Shuang Xu; Bei Guo; Ling-Qing Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-20       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.